If you are worried about your gallbladder on the shot, here is the honest, calm version. GLP-1 receptor agonists (semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro and Zepbound) are linked to a modestly higher risk of gallbladder and biliary problems, mostly gallstones and, less often, gallbladder inflammation. Two things seem to drive it: losing weight quickly, which is itself a long-known cause of gallstones, and the medicine gently slowing the gallbladder down. The key word is associated. Much of the signal tracks with how fast and how much weight you lose rather than being proven to come from the drug alone. The absolute risk stays low. But it is real, and a gallbladder attack has a recognizable pattern that is worth knowing tonight. This is general information, not medical advice. Talk to your prescriber about your own situation.
Why the Ozempic gallbladder risk happens
First, the reassuring part: most people on a GLP-1 never run into a gallbladder problem at all. This is not something to brace yourself for every day. It is something to recognize if it ever shows up.
Here is what is actually going on. Your gallbladder is a small pouch that stores bile and squeezes it out to help you digest fat. Two overlapping things help explain why the shot is linked to gallbladder trouble.
The first is losing weight quickly, and it is not unique to these medicines. When the body sheds weight fast, the liver dumps extra cholesterol into bile and the gallbladder empties less often, so bile sits still and stones are more likely to form. The NIDDK explains this is why rapid weight loss raises the risk of gallstones, and why it suggests a gradual pace instead of crash dieting. Because GLP-1 medicines can produce a lot of weight loss, they carry that same well-known risk along with the loss itself.
The second is a direct effect on the gallbladder: the medicines appear to make the gallbladder contract less actively, which lets bile linger longer. This slowed-gallbladder idea is a leading explanation rather than settled fact, but it fits what the trials show. Risk runs higher at higher doses, with longer use, and at weight-loss dosing compared with diabetes dosing.
How common is it?
The honest answer is uncommon, but more common than placebo. There are two kinds of numbers worth keeping separate: the per-dose percentages from individual trials, and a pooled relative-risk estimate from many trials at once.
From the trials behind the prescribing information:
- The semaglutide (Ozempic) prescribing information reports gallstones (cholelithiasis) in about 1.5% of people at one dose and 0.4% at another, versus 0% on placebo.
- The tirzepatide (Zepbound) prescribing information reports gallstones in about 1.1% versus 1.0% on placebo, gallbladder inflammation (cholecystitis) in about 0.7% versus 0.2%, and gallbladder removal (cholecystectomy) in about 0.2% versus 0%. It notes that the acute gallbladder events were tied to weight reduction.
Pooling the bigger picture, a large meta-analysis in JAMA Internal Medicine (He and colleagues, 2022; 76 randomized trials, 103,371 patients) found GLP-1 use associated with gallbladder or biliary disease at a relative risk of 1.37 (95% CI 1.23 to 1.52), which works out to roughly 27 extra events per 10,000 people treated per year. Two details make that number fairer to read. First, the relative risk was much higher at weight-loss dosing (RR 2.29) than at diabetes dosing (RR 1.27), which fits the idea that weight loss itself drives a lot of the effect. Second, a relative risk is not an absolute one. A 37% higher relative risk still leaves the absolute risk low, because the starting baseline is small. The per-dose percentages above are observed trial rates; the relative risks are pooled estimates. Different kinds of numbers, pointing the same direction.
The warning signs to watch for
This is the part to actually remember. A gallbladder attack, or an inflamed gallbladder (cholecystitis), has a fairly recognizable signature. Cleveland Clinic describes the classic gallbladder attack symptoms, and the pattern looks like this:
- Steady, severe pain in the upper-right or upper-middle part of your belly, often coming on after a fatty or heavy meal.
- Pain that spreads to your right shoulder or your back.
- Fever or chills.
- Nausea or vomiting along with the pain.
- Yellowing of your skin or the whites of your eyes (jaundice).
- Clay-colored or pale stools.
A brief, mild twinge that passes in seconds is not the same thing. The pattern that matters is the steady one: pain under the right ribs or high in the belly that lingers for hours rather than passing quickly, especially after fatty food, and most of all if it comes with fever, vomiting, or any yellowing.
What you can do
None of these are a reason to skip or change your dose on your own. They are typical, prescriber-directed considerations, the calm and sensible things to keep in mind.
- A gradual pace of weight loss is the main lever. Because the risk tracks so closely with fast loss, easing the rate helps. The NIDDK points to gradual weight loss, roughly 5 to 10% over about six months, and avoiding crash diets. How that pace is reached, including any dose pacing, belongs to your prescriber, not to a forum and not to a self-adjustment.
- Stay under medical monitoring. The semaglutide prescribing information says that if gallstones are suspected, gallbladder studies and appropriate follow-up are indicated. That is your clinician's call to make if symptoms appear.
- Report symptoms early rather than waiting them out, so they can be looked at before they escalate.
For the bigger picture on what eases and when across the whole GLP-1 experience, see how long GLP-1 side effects last.
When to call someone
Gallbladder problems on a GLP-1 are uncommon, and most people sail right past them. The reason to know the signs is simple: a gallbladder attack is one of the few situations on the shot where telling the difference quickly, and getting evaluated, genuinely matters.
Questions people ask at 11pm
Does Ozempic cause gallstones? It is associated with a modestly higher risk of gallstones, not proven to cause them on its own. Much of the signal tracks with rapid or substantial weight loss, which is itself a long-known cause of gallstones, and semaglutide may also slow the gallbladder down. The same goes for tirzepatide (Mounjaro, Zepbound). The absolute risk stays low.
How much does the risk actually go up? A large meta-analysis put the relative risk of gallbladder or biliary disease at about 1.37, or roughly 27 extra events per 10,000 people treated per year. It was higher at weight-loss dosing (about 2.29) than at diabetes dosing (about 1.27). Because the baseline is small, the absolute risk stays low.
How do I know if it is a gallbladder attack and not just gas? A gallbladder attack is usually steady, severe pain in the upper-right or upper-middle belly that lasts hours, often after a fatty meal, sometimes spreading to the right shoulder or back. Pain with fever, chills, vomiting, or jaundice (yellow skin or eyes) needs urgent care. Ordinary gas tends to be crampy, shifting, and short, and it eases when it passes.
How we reviewed this: this page was written from authoritative sources, including the He et al. meta-analysis in JAMA Internal Medicine, the NIDDK on dieting and gallstones, and Cleveland Clinic on gallbladder disease. Per-dose rates are attributed to the semaglutide (Ozempic) and tirzepatide (Zepbound) prescribing information; see the Ozempic label on DailyMed. See our editorial and review policy and sourcing standards. Where the evidence is an association rather than proven sole causation, much of the signal tracks with the rate and amount of weight loss, and the slowed-gallbladder detail is a leading explanation rather than settled fact, we say so rather than overstating it.
Every medical claim above is cited to a primary source such as an FDA label, the NIH, or a named clinical trial. See how we review and our sourcing & fact-check standards.